We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Valeant Pharmaceuticals says that the FDA has noted improvements at its plant in Florida whose manufacturing issues have kept it from getting an approval for a new eye drug.